Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

STIM
Neuronetics, Inc. Common Stock
stock NASDAQ

At Close
Jan 29, 2026 3:59:44 PM EST
2.20USD+3.774%(+0.08)767,200
2.19Bid   2.21Ask   0.02Spread
Pre-market
Jan 29, 2026 9:17:30 AM EST
2.14USD+0.943%(+0.02)4,125
After-hours
Jan 28, 2026 4:22:30 PM EST
2.11USD-0.915%(-0.02)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
08:34AM EST  Neuronetics 8-K Shows Co. Raises Q4 Sales Guidance From $13M-$14M To $14.5M-$15M vs $13.5M Estimate; FY21 From $53.3M-$54.3M To $54.8M-$55.3M vs $53.8M Est.   Benzinga
08:31AM EST  NeuroStar Advanced Therapy for Mental Health Recognized as Top   GlobeNewswire Inc
08:30AM EST  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced certain preliminary unaudited fourth quarter and full year 2021 revenue results.   GlobeNewswire Inc
Dec 20, 2021
08:36AM EST  Neuronetics Announces 510(k) Clearance Of MT Cap Technology For NeuroStar Advanced Therapy For Mental Health   Benzinga
08:31AM EST  Neuronetics Announces 510(k) Clearance of MT Cap Technology for   GlobeNewswire Inc
Dec 13, 2021
09:43AM EST  Neuronetics Granted FDA Approval For NeuroStar TSM Therapy System. BZ NOTE: FDA Site Shows Decision Date Of 12/10/2021   Benzinga
Dec 6, 2021
08:31AM EST  Neuronetics Announces Key Role for NeuroStar Advanced Therapy at   GlobeNewswire Inc
Nov 22, 2021
04:41PM EST  Neuronetics To Participate At The Piper Sandler 33rd Annual Virtual Healthcare Conference   Benzinga
04:30PM EST  Neuronetics to Participate at the Piper Sandler 33rd Annual   GlobeNewswire Inc
Nov 9, 2021
11:38AM EST  Neuronetics Sees FY21 Revs $53.3M-$54.3M   Benzinga
11:37AM EST  Neuronetics Q3 EPS $(0.31) Misses $(0.30) Estimate, Sales $13.80M Miss $14.10M Estimate   Benzinga
11:25AM EST  Earnings Scheduled For November 9, 2021   Benzinga
07:30AM EST  Neuronetics,Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced its financial and operating results for the third quarter of 2021.   GlobeNewswire Inc
Nov 8, 2021
10:03AM EST  Neuronetics, River Region Psychiatry Announce Exclusive Partnership   Benzinga
10:00AM EST  Partnership Will Bring Non-drug NeuroStar Advanced Therapy For Mental Health To Thousands of Patients Across the Southeast   GlobeNewswire Inc
Nov 1, 2021
09:00AM EDT  Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on earlyintervention orthopedics, today announced that its Board of Directors has appointed Sheryl Conley as independent director, effective October 28, 2021.   GlobeNewswire Inc
Oct 26, 2021
08:30AM EDT  Neuronetics Celebrates 235,000 Treatment Milestone for Success TMS   GlobeNewswire Inc
08:30AM EDT  Neuronetics to Report Third Quarter 2021 Financial and Operating   GlobeNewswire Inc
Oct 19, 2021
08:15PM EDT  In a release issued under the same headline on Tuesday, October 12th from Neuronetics, Inc. (NASDAQ: STIM), please note that the Safe Harbor Statement was inadvertently omitted. No changes were made to the content of the press release and the Safe Harbor Statement has been added, the corrected release follows:   GlobeNewswire Inc
08:32AM EDT  Neuronetics Highlights Launch Of Upgrade For NeuroStar Advanced Therapy System   Benzinga
08:31AM EDT  System Innovations Improve Efficiencies for Healthcare Practices and Patients   GlobeNewswire Inc
Oct 14, 2021
08:42AM EDT  JMP Securities Maintains Market Outperform on Neuronetics, Lowers Price Target to $12   Benzinga
Oct 13, 2021
03:11PM EDT  Mid-Afternoon Market Update: Nasdaq Jumps 100 Points; Jasper Therapeutics Shares Spike Higher   Benzinga
01:39PM EDT  Mid-Day Market Update: Gold Surges 2%; Neuronetics Shares Plunge   Benzinga
01:38PM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2021   Benzinga
01:38PM EDT  Mid-Morning Market Update: Markets Mixed; JPMorgan Posts Upbeat Earnings   Benzinga
01:38PM EDT  The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal   Benzinga
06:19AM EDT  BTIG Downgrades Neuronetics to Neutral   Benzinga
Oct 12, 2021
04:18PM EDT  Neuronetics Cuts Q3 Sales Guidance From $15M-$16M To ~$13.8M Vs. $15.07M Est., Cuts FY21 Sales From $59M-$63M To $53.3M-$54.3M Vs. $59.33M Est.   Benzinga
04:15PM EDT  Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today provided preliminary revenue results for the third quarter of 2021.   GlobeNewswire Inc
Oct 5, 2021
04:15PM EDT  Neuronetics Reports Commercial Deal With Success TMS   Benzinga
04:15PM EDT  Neuronetics Announces Commercial Agreement with Success TMS   GlobeNewswire Inc
Oct 4, 2021
08:40AM EDT  NeuroStar Advanced Therapy Recognizes National   GlobeNewswire Inc
Sep 22, 2021
06:33PM EDT  UPDATE - New Data Highlights NeuroStar Advanced   GlobeNewswire Inc
Sep 21, 2021
08:33AM EDT  Neuronetics Highlights New Data On NeuroStar Advanced Therapy For Mental Health Safety Over H-Coil TMS   Benzinga
08:30AM EDT  New Data Highlights NeuroStar Advanced Therapy for   GlobeNewswire Inc
Sep 7, 2021
08:36AM EDT  Neuronetics To Be Exclusive Supplier Of TMS Equipment To Zion Healing   Benzinga
08:30AM EDT  Neuronetics and Zion Healing Announce First Franchise Model for   GlobeNewswire Inc
Sep 1, 2021
07:32AM EDT  The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering   Benzinga
Aug 17, 2021
08:44AM EDT  Neuronetics Highlights Launch Of New Website To Meet Patient Demand For Depression Resources   Benzinga
08:31AM EDT  Neuronetics Launches New Website to Meet Patient Demand for   GlobeNewswire Inc
Aug 3, 2021
02:31PM EDT  Mid-Afternoon Market Update: Dow Jumps Over 200 Points; Neuronetics Shares Plunge   Benzinga
12:35PM EDT  Mid-Morning Market Update: Markets Down; Alibaba Posts Downbeat Q1 Sales   Benzinga
12:12PM EDT  Mid-Day Market Update: Crude Oil Down 2%; Arcturus Therapeutics Shares Spike Higher   Benzinga
11:18AM EDT  Shares of Neuronetics Inc. (STIM) tanked over 40% on Tuesday morning after its second-quarter results missed street estimates.   RTTNews
10:15AM EDT  Mid-Morning Market Update: Markets Down; Alibaba Posts Downbeat Q1 Sales   Benzinga
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
07:38AM EDT  Neuronetics Sees Q3 Sales $15M-$16M vs $16.51M Est., Sees FY21 Sales $59M-$63M vs $61.67M Est.   Benzinga
07:36AM EDT  Neuronetics Q2 EPS $(0.29) Misses $(0.24) Estimate, Sales $14.20M Miss $14.72M Estimate   Benzinga
07:30AM EDT  Neuronetics,Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced its financial and operating results for the second quarter of 2021.   GlobeNewswire Inc
03:52AM EDT  Earnings Scheduled For August 3, 2021   Benzinga
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 29, 2021
08:30AM EDT  Neuronetics to Present at the Canaccord Genuity 41st Annual Growth   GlobeNewswire Inc
Jul 20, 2021
08:30AM EDT  Neuronetics to Report Second Quarter 2021 Financial and Operating   GlobeNewswire Inc
Jul 14, 2021
08:17AM EDT  Neuronetics Launches Enhanced Digital Resource Center for   GlobeNewswire Inc
Jun 24, 2021
08:12AM EDT  The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO   Benzinga
Jun 23, 2021
05:29PM EDT  Neuronetics Set to Join Russell 2000 Index   GlobeNewswire Inc
Jun 9, 2021
08:00AM EDT  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today it will present real-world clinical data as part of the Clinical TMS Society (CTMSS) Annual Meeting.   GlobeNewswire Inc
Jun 3, 2021
08:00AM EDT  Neuronetics to Present at The JMP Securities Life Sciences Conference   GlobeNewswire Inc
Jun 1, 2021
08:00AM EDT  Neuronetics Names Todd Cushman as Vice President, Business Development   GlobeNewswire Inc
May 20, 2021
08:00AM EDT  Neuronetics to Present at the William Blair 41st Annual Growth   GlobeNewswire Inc
May 17, 2021
08:00AM EDT  Neuronetics Celebrates 100,000 Treatment Milestone for   GlobeNewswire Inc
May 4, 2021
03:00PM EDT  Mid-Afternoon Market Update: Nasdaq Tumbles 300 Points; Neuronetics Shares Spike Higher   Benzinga
12:20PM EDT  Mid-Day Market Update: Maxar Technologies Falls After Q1 Results; BioLineRx Shares Climb   Benzinga
08:10AM EDT  The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data   Benzinga
07:35AM EDT  Neuronetics Raises FY21 Sales Guidance From $58M-$62M To $59M-$63M vs $60.67M Est.   Benzinga
07:33AM EDT  Neuronetics Q1 EPS $(0.31), Inline, Sales $12.29M Beat $11.58M Estimate   Benzinga
07:00AM EDT  Neuronetics,Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced its financial and operating results for the first quarter of 2021.   GlobeNewswire Inc
May 3, 2021
08:00AM EDT  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, is honoring the depression journeys of its employees and all those who suffer from depression in observance of Mental Health Awareness Month.   GlobeNewswire Inc
Apr 29, 2021
08:00AM EDT  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today it will present clinical data in virtual poster sessions as part of the American Psychiatric Associations Annual Meeting virtual programming.   GlobeNewswire Inc
Apr 20, 2021
08:00AM EDT  Neuronetics to Report First Quarter 2021 Financial and Operating   GlobeNewswire Inc
Apr 15, 2021
07:49AM EDT  The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split   Benzinga
Apr 14, 2021
05:15PM EDT  Neuronetics Announces Retirement of Brian Farley and Appointment   GlobeNewswire Inc
Apr 1, 2021
04:05PM EDT  Neuronetics Announces Appointment of Robert Cascella to its Board   GlobeNewswire Inc
Mar 11, 2021
04:25PM EST  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Gregory Harper, the companys Vice President, R&D and Clinical, will retire effective March 31, 2021.   GlobeNewswire Inc
Mar 9, 2021
09:17AM EST  Neuronetics Says Enhances TrakStar Cloud Patient Data Management System To 'Maximize Physician Efficiencies'   Benzinga
08:00AM EST  Neuronetics Enhances TrakStar Cloud Patient Data   GlobeNewswire Inc
Mar 3, 2021
08:00AM EST  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced Cory Anderson has been appointed the companys Vice President, Clinical Affairs and Medical Operations effective as of March 1.   GlobeNewswire Inc
Mar 2, 2021
08:01AM EST  The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data   Benzinga
07:57AM EST  Neuronetics: Q4 Earnings Insights   Benzinga
07:36AM EST  Neuronetics Q4 EPS $(0.19) Beats $(0.24) Estimate, Sales $15.60M Beat $14.40M Estimate   Benzinga
07:30AM EST  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced its financial and operating results for the fourth quarter and full year of 2020.   GlobeNewswire Inc
03:40AM EST  Earnings Scheduled For March 2, 2021   Benzinga
Mar 1, 2021
10:12AM EST  Earnings Outlook For Neuronetics   Benzinga
Feb 27, 2021
09:04PM EST  The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings   Benzinga
Feb 23, 2021
08:00AM EST  NeuroStar Advanced Therapy Outcomes Registry Clinical   GlobeNewswire Inc
Feb 16, 2021
07:00AM EST  Neuronetics to Report Fourth Quarter and Fiscal Year 2020   GlobeNewswire Inc
Feb 11, 2021
08:00AM EST  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced three executive leadership team promotions to support the Companys strategic growth plans.   GlobeNewswire Inc
Feb 10, 2021
07:00AM EST  Neuronetics to Participate at the BTIG Virtual MedTech, Digital   GlobeNewswire Inc
Feb 2, 2021
04:05PM EST  Neuronetics Announces Closing of Public Offering and Exercise in   GlobeNewswire Inc
Jan 29, 2021
07:45AM EST  The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO   Benzinga
Jan 28, 2021
10:31PM EST  Neuronetics Prices 4.84M Shares Of Common Stock At $15.50/Share   Benzinga
04:03PM EST  Neuronetics Announces Proposed Public Offering of Common Stock; No Terms Disclosed   Benzinga
Jan 22, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 22, 2021   Benzinga
07:41AM EST  William Blair Upgrades Neuronetics to Outperform   Benzinga
07:22AM EST  The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa   Benzinga
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 19, 2021
08:16AM EST  Neuronetics Reports Co's NeuroStar Advanced Therapy's Depression Outcomes Registry Hits 10,000 Patient Milestone   Benzinga
08:00AM EST  NeuroStar Advanced Therapys   GlobeNewswire Inc
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 14, 2021
07:57AM EST  The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates   Benzinga
Jan 13, 2021
07:25AM EST  The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations   Benzinga
Jan 12, 2021
04:06PM EST  Neuronetics Sees Q4 2020 Revs $15M-$15.5M Vs Est $13.08M-$13.3M   Benzinga
04:05PM EST  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today, in advance of the ICR/Westwicke Conference, announced certain preliminary unaudited fourth quarter and full year 2020 revenue results.   GlobeNewswire Inc
Jan 8, 2021
07:25AM EST  The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs   Benzinga
Jan 7, 2021
04:30PM EST  Neuronetics to Participate at the 23rd Annual ICR Westwicke Conference   GlobeNewswire Inc
08:14AM EST  Neuronetics Announces Expansion Of Its Commercial Organization   RTTNews
08:03AM EST  Neuronetics Announces Expansion Of Sales Organization   Benzinga
08:00AM EST  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the expansion of its commercial organization.   GlobeNewswire Inc
Dec 29, 2020
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 10, 2020
07:42AM EST  The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations   Benzinga
Dec 8, 2020
04:05PM EST  Neuronetics Announces the Amendment of Credit Facility   GlobeNewswire Inc
Dec 2, 2020
07:35AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod   Benzinga
Dec 1, 2020
08:08AM EST  The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit   Benzinga
Nov 30, 2020
04:05PM EST  Neuronetics to Participate in the Piper Sandler 32nd Annual   GlobeNewswire Inc
Nov 24, 2020
08:13AM EST  The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia   Benzinga
Nov 23, 2020
04:05PM EST  Neuronetics Receives FDA Clearance for Three-Minute   GlobeNewswire Inc
04:05PM EST  Neuronetics Receives FDA Clearance For Three-Minute TouchStar Treatment Protocol   Benzinga
Nov 18, 2020
07:30AM EST  The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted   Benzinga
Nov 17, 2020
08:32AM EST  The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration   Benzinga
Nov 12, 2020
04:05PM EST  Neuronetics to Present at the Canaccord Genuity Virtual MedTech &   GlobeNewswire Inc
07:44AM EST  The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal   Benzinga
Nov 10, 2020
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
Nov 2, 2020
04:26PM EST  Neuronetics Sees FY 2020 Revenue Between $46.7M And $47.2M, Operating Expenses Between $59M And $61M   Benzinga
04:25PM EST  Neuronetics Q3 EPS $(0.18) Beats $(0.27) Estimate, Sales $12.40M Beat $11.56M Estimate   Benzinga
04:05PM EST  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced its financial and operating results for the third quarter of 2020.   GlobeNewswire Inc
07:55AM EST  Earnings Scheduled For November 2, 2020   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 26, 2020
09:54AM EDT  Canaccord Genuity Maintains Buy on Neuronetics, Raises Price Target to $8   Benzinga
Oct 19, 2020
04:05PM EDT  Neuronetics to Report Third Quarter 2020 Financial and Operating   GlobeNewswire Inc
Oct 13, 2020
08:15AM EDT  Neuronetics Reports Journal Of Affective Disorders Publishes Clinical Data Suggesting NeuroStar Advanced Therapy As A First-Line Treatment For Major Depressive Disorder   Benzinga
08:00AM EDT  Journal of Affective Disorders Publishes Clinical Data Suggesting   GlobeNewswire Inc
Oct 6, 2020
02:28PM EDT  Why Neuronetics Stock Is Trading Higher Today   Benzinga
08:08AM EDT  BTIG Reiterates Buy on Neuronetics, Raises Price Target to $10   Benzinga
Oct 5, 2020
08:14AM EDT  Neuronetics Names Sara Grubbs VP, Sales   RTTNews
08:00AM EDT  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on improving the lives of patients who suffer from psychiatric disorders, announced that Sara Grubbs has been appointed as the companys Vice President, Sales effective immediately.   GlobeNewswire Inc
Oct 1, 2020
08:00AM EDT  NeuroStar Advanced Therapy Providers Offer Free TMS   GlobeNewswire Inc
Sep 29, 2020
08:00AM EDT  Neuronetics Celebrates 500,000 Treatment Milestone for   GlobeNewswire Inc
Sep 22, 2020
08:03AM EDT  Neuronetics Unveils New Depression Data At Clinical TMS Society's Virtual Events   Benzinga
08:00AM EDT  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, will present clinical data and host virtual educational sessions as part of the Clinical TMS Societys virtual programming.   GlobeNewswire Inc
Aug 4, 2020
07:52AM EDT  Neuronetics Q2 EPS $(0.41) Beats $(0.51) Estimate, Sales $9.70M Beat $8.20M Estimate   Benzinga
07:30AM EDT  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced its financial and operating results for the second quarter of 2020.   GlobeNewswire Inc
05:19AM EDT  Earnings Scheduled For August 4, 2020   Benzinga
Jul 21, 2020
08:00AM EDT  Neuronetics to Report Second Quarter 2020 Financial and Operating   GlobeNewswire Inc
Jul 17, 2020
04:05PM EDT  Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule   GlobeNewswire Inc
Jul 14, 2020
04:16PM EDT  Neuronetics Names Keith Sullivan President And CEO   RTTNews
04:16PM EDT  Neuronetics Announces the Appointment of Keith J. Sullivan as President and   PR Newswire
04:06PM EDT  Neuronetics Names Keith Sullivan Pres, CEO   Benzinga
04:05PM EDT  Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on improving the lives of patients who suffer from psychiatric disorders, announced that Keith J. Sullivan has been appointed as the companys President and Chief Executive Officer and has joined the Board of Directors effective immediately.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC